Pelthos Therapeutics (PTHS) Share-based Compensation (2023 - 2026)
Pelthos Therapeutics (PTHS) posted quarterly Share-based Compensation of $1.8 million for Q4 2025, up 239.43% year-over-year from $530000.0 in Q4 2024, and down 36.02% quarter-over-quarter from $2.8 million in Q3 2025.
Pelthos Therapeutics (PTHS) Share-based Compensation (2023 - 2026) Analysis & Trends
Pelthos Therapeutics' Share-based Compensation history runs 3 years deep, the most recent figure standing at $1.8 million for Q4 2025.
- In Q4 2025, Share-based Compensation rose 239.43% year-over-year to $1.8 million; the TTM figure through Dec 2025 stood at $5.5 million (up 220.64% YoY), while the FY2025 annual figure was $5.5 million, up 203.56% from the prior year.
- Share-based Compensation for Q4 2025 stood at $1.8 million, down from $2.8 million in the prior quarter.
- The five-year high for Share-based Compensation was $2.8 million in Q3 2025, with the low at $272221.0 in Q1 2023.
- The 3-year median for Share-based Compensation is $447989.0 (2024), against an average of $746840.0.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation tumbled 33.02% in 2024, then soared 543.48% in 2025.
- Pelthos Therapeutics' Share-based Compensation stood at $791244.0 in 2023, then sank by 33.02% to $530000.0 in 2024, then jumped by 239.43% to $1.8 million in 2025.
- Business Quant data shows PTHS's Share-based Compensation at $1.8 million in Q4 2025, $2.8 million in Q3 2025, and $413486.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Pelthos Therapeutics | 91.09 Mn | 66.53 Mn | 21.23 Mn | 4.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.67 Mn |
| Jun 30, 2026 | 4.67 Mn |
| Dec 31, 2025 | 1.80 Mn |
| Dec 31, 2025 | 1.80 Mn |
| Sep 30, 2025 | 2.81 Mn |
| Sep 30, 2025 | 2.81 Mn |
| Jun 30, 2025 | 413,486.00 |
| Jun 30, 2025 | 413,486.00 |
| Mar 31, 2025 | 485,831.00 |
| Mar 31, 2025 | 485,831.00 |
| Dec 31, 2024 | 530,000.00 |
| Dec 31, 2024 | 530,000.00 |
| Sep 30, 2024 | 437,000.00 |
| Sep 30, 2024 | 437,000.00 |
| Jun 30, 2024 | 458,978.00 |
| Jun 30, 2024 | 458,978.00 |
| Mar 31, 2024 | 292,552.00 |
| Mar 31, 2024 | 292,552.00 |
| Dec 31, 2023 | 791,244.00 |
| Dec 31, 2023 | 791,244.00 |